Encodia, Inc.

Encodia, Inc. is a biotechnology company specializing in advanced protein sequencing technologies that enhance understanding of cellular processes for personalized medicine. Their innovative solutions facilitate comprehensive data analysis for researchers and healthcare organizations. Founded in 2015 in San Diego, US, Encodia, Inc.

specializes in protein sequencing using proprietary technologies. The company was established by Kevin Gunderson and Michael Weiner. In January 2021, Encodia raised USD 75. 78 mn in a Series C funding round, attracting notable investors such as Deerfield Management and Northpond Ventures.

The total amount raised by the company now stands at USD 75. 78 mn, with a current valuation of USD 216. 49 mn. Encodia’s core product offering centers around its proprietary ProteoCode™ technology, which enables large-scale protein sequencing through a novel approach known as reverse-translation.

This technology is designed to enhance the understanding of cellular processes, facilitating advancements in personalized medicine. By utilizing next-generation sequencing (NGS) techniques and amino acid barcoded libraries, Encodia’s solutions integrate seamlessly with multiomic approaches to provide comprehensive data analysis. The company’s products are particularly valuable to researchers and institutions engaged in population-level studies and those requiring in-depth insights into protein activity and interactions, primarily serving customers in North America and Europe, including academic research institutions and pharmaceutical companies. Encodia's revenue model is primarily based on B2B transactions, involving partnerships and collaborations with research institutions and biotechnology companies.

The company engages in agreements where clients access its ProteoCode™ technology and related services, typically structured around multi-year contracts or project-based collaborations. These arrangements often involve tiered pricing based on project scale and complexity, ensuring that clients receive tailored solutions that meet their specific needs. Key clients benefit from ongoing support and updates, which may include access to advanced analytical tools and consultation services as part of their engagement with Encodia. Moving forward, Encodia plans to design new products leveraging its ProteoCode™ technology with anticipated releases aimed at expanding its market reach, particularly into new geographic regions.

The company aims to enhance its presence in Europe and Asia by 2023. The recent Series C funding of USD 75. 78 mn will be utilized to support these new product developments and facilitate market entry strategies in the targeted regions, strengthening its commitment to advancing biotechnological applications.